- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02835313
Promoting Recovery Optimization With WALKing Exercise After Stroke (PROWALKS)
October 24, 2024 updated by: University of Delaware
Stroke survivors, as a group, are extremely inactive and this has serious consequences for them, including an increased risk of a second stroke and developing other diseases.
This study investigates a novel intervention designed to improve everyday activity after stroke by combining walking training to improve walking capacity with a program to encourage more daily walking.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
As a group, stroke survivors are more physically inactive than even the most sedentary older adults.
Lack of physical activity has serious consequences in persons with stroke, including an increased risk of recurrent stroke, developing other diseases and mortality.
Current rehabilitation interventions do little to improve real-world walking activity after stroke, suggesting that simply improving walking capacity is not sufficient for improving daily physical activity after stroke.
Rather, the investigator's hypothesize that the combination of a fast walking intervention that improves walking capacity, with a step activity monitoring program that facilitates translation of gains from the clinic to the "real-world", would generate greater improvements in real world walking activity than with either intervention alone.
Data from the investigator's lab provides support for this hypothesis; however, it suggests that the greater efficacy of combining the 2 interventions depends on a participant's initial walking activity.
Thus, the investigator's do not expect that one intervention will be superior to the others for all participants, but rather that the combined intervention will be superior for those with low levels of baseline walking activity, speed and endurance.
The specific objective of this study is to test whether and for whom combining fast walking training with a step activity monitoring program (FAST+SAM) is superior in improving real-world walking activity compared to fast walking training alone (FAST) or a step activity monitoring and feedback program alone (SAM) in those with chronic stroke.
Using a randomized controlled experimental design, 225 chronic (> 6 months) stroke survivors, will complete 12 weeks of fast walking training (FAST), a step activity monitoring program (SAM) or a fast walking training + step activity monitoring program (FAST+SAM).
Moderation of specific intervention outcomes by baseline characteristics will be evaluated to determine for whom the interventions are effective.
Study Type
Interventional
Enrollment (Actual)
250
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Delaware
-
Newark, Delaware, United States, 19712
- University of Delaware
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age 21-85
- Chronic stroke (>6 months post stroke)
- Able to walk at self-selected speed without assistance from another person (assistive devices are allowed)
- Self-selected walking speed >0.3 m/s and <1.0 m/s
- Average steps/day <8,000
- Resting heart rate between 40-100 beats per minute
- Resting blood pressure between 90/60 to 170/90.
Exclusion Criteria:
- Evidence of cerebellar stroke
- Other potentially disabling neurologic conditions in addition to stroke
- Lower limb Botulinum toxin injection <4 months earlier
- Current participation in physical therapy
- Inability to walk outside the home prior to the stroke
- Coronary artery bypass graft, stent placement or myocardial infarction within past 3 months
- Musculoskeletal pain that limits activity
- Inability to communicate with investigators
- score >1 on question 1b and >0 on question 1c on the NIH Stroke Scale.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: FAST+SAM
Subjects participate in fast walking training in combination with a step activity monitoring program
|
Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
|
|
Active Comparator: FAST alone
Subjects participate in fast walking training
|
Subjects participate in fast walking training 3x/week for 12 weeks.
|
|
Active Comparator: SAM alone
Subjects participate in a step activity monitoring program
|
Subjects participate in a step activity monitoring program 3x/week for 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Steps Per Day
Time Frame: Change from Baseline to 3 months (Post)
|
average change in steps per day between two time points, measured over at least a 3-day period for each time point
|
Change from Baseline to 3 months (Post)
|
|
Steps Per Day
Time Frame: Change from 3 months (Post) to 6 months
|
average change in steps per day between two time points, measured over at least a 3-day period for each time point
|
Change from 3 months (Post) to 6 months
|
|
Steps Per Day
Time Frame: Change from 3 months (Post) to 12 months
|
average change in steps per day between two time points, measured over at least a 3-day period for each time point
|
Change from 3 months (Post) to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Six-minute Walk Test Distance
Time Frame: Change from Baseline to 3 months (Post)
|
change between two time points in endurance (measured by distance attained on the 6 minute walk test)
|
Change from Baseline to 3 months (Post)
|
|
Six-minute Walk Test Distance
Time Frame: Change from 3 months (Post) to 6 months
|
change between two time points in endurance (measured by distance attained on the 6 minute walk test)
|
Change from 3 months (Post) to 6 months
|
|
Six-minute Walk Test Distance
Time Frame: Change from 3 months (Post) to 12 months
|
change between two time points in endurance (measured by distance attained on the 6 minute walk test)
|
Change from 3 months (Post) to 12 months
|
|
Self-selected Gait Speed
Time Frame: Change from Baseline to 3 months (Post)
|
change between two time points in average self-selected speed on the 10m walk test
|
Change from Baseline to 3 months (Post)
|
|
Self-selected Gait Speed
Time Frame: Change from 3 months (Post) to 6 months
|
change between two time points in average self-selected speed on the 10m walk test
|
Change from 3 months (Post) to 6 months
|
|
Self-selected Gait Speed
Time Frame: Change from 3 months (Post) to 12 months
|
change between two time points in average self-selected speed on the 10m walk test
|
Change from 3 months (Post) to 12 months
|
|
Oxygen Consumption
Time Frame: Change from Baseline to 3 months (Post)
|
change between two time points in average oxygen consumption at ventilatory threshold
|
Change from Baseline to 3 months (Post)
|
|
Oxygen Consumption
Time Frame: Change from 3 months (Post) to 6 months
|
change between two time points in average oxygen consumption at ventilatory threshold
|
Change from 3 months (Post) to 6 months
|
|
Oxygen Consumption
Time Frame: Change from 3 months (Post) to 12 months
|
change between two time points in average oxygen consumption at ventilatory threshold
|
Change from 3 months (Post) to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Darcy Reisman, PT, PhD, University of Delaware
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Andreasen SC, Wright TR, Crenshaw JR, Reisman DS, Knarr BA. Relationships of Linear and Non-linear Measurements of Post-stroke Walking Activity and Their Relationship to Weather. Front Sports Act Living. 2020 Nov 3;2:551542. doi: 10.3389/fspor.2020.551542. eCollection 2020.
- Wright H, Wright T, Pohlig RT, Kasner SE, Raser-Schramm J, Reisman D. Protocol for promoting recovery optimization of walking activity in stroke (PROWALKS): a randomized controlled trial. BMC Neurol. 2018 Apr 12;18(1):39. doi: 10.1186/s12883-018-1044-1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 18, 2016
Primary Completion (Actual)
January 1, 2023
Study Completion (Actual)
December 1, 2023
Study Registration Dates
First Submitted
July 11, 2016
First Submitted That Met QC Criteria
July 15, 2016
First Posted (Estimated)
July 18, 2016
Study Record Updates
Last Update Posted (Actual)
October 28, 2024
Last Update Submitted That Met QC Criteria
October 24, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIH 1R01HD086362-01A1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified data will be deposited in the National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub (DASH) repository.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
National Assembly ClinicBayero University Kano, NigeriaRecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After StrokeNigeria
-
University of PittsburghRecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, EmbolicUnited States
-
Mahidol UniversityNot yet recruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke SurvivorsThailand
-
Mahidol UniversityRecruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke PatientThailand
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
Fondazione Don Carlo Gnocchi OnlusScuola Superiore Sant'Anna di Pisa; Fondazione Policlinico Universitario Campus...Not yet recruitingStroke | Stroke Hemorrhagic | Upper Limb Rehabilitation | Stroke IschemicItaly
-
Samsung Medical CenterCompletedChronic Stroke | Subacute Stroke | ExoskeletonSouth Korea
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
Clinical Trials on FAST+SAM
-
PfizerCompleted
-
M.D. Anderson Cancer CenterAstraZenecaRecruitingAdenoid Cystic CarcinomaUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAlzheimer DiseaseNetherlands
-
Wyeth is now a wholly owned subsidiary of PfizerTerminatedAlzheimer DiseaseFrance
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
ZetrOZ, Inc.CompletedTendinopathy | Tendinosis | TendinitisUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAlzheimer DiseaseUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAlzheimer DiseaseJapan
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted